Adicet Bio (ACET)

The company’s platform combines gamma delta T cells with chimeric antigen receptor, or CAR, technology. Gamma delta T cells are a distinct subset of immune cells that may offer advantages in recognizing diseased tissue and being used across multiple patients. Adicet engineers these cells to target specific disease markers, with the goal of creating therapies that can produce durable clinical activity in autoimmune diseases and cancer.

Adicet’s lead product candidate is prulacabtagene leucel, commonly referred to as prula-cel. It is an allogeneic gamma delta T cell therapy carrying a CAR directed at CD20, a target found on B cells. The company is developing prula-cel for potential use in autoimmune diseases, where depletion or modulation of disease-driving B cells may be therapeutically useful.

The pipeline also includes ADI-212, a next-generation gene-edited and armored candidate designed to target prostate-specific membrane antigen, or PSMA, a marker associated with prostate cancer. As with many biotechnology companies at the clinical stage, Adicet’s value is closely linked to trial progress, regulatory outcomes, platform validation and its ability to finance development.